Inclusion Criteria:

• 1. Patient or patient's legal representative(s) provided written informed consent to participate in a gene transfer study at the University of Texas MD Anderson Cancer Center (MD Anderson).
• 2. Patient will receive vector or vector-treated cells at MD Anderson.
• 3. Patient or patient's legal representative(s) is/are able to provide written informed consent to participate in this long-term follow-up protocol for gene transfer participants for up to 15 years following administration of gene therapy product.
• 4. Agree to allow clinical samples to be collected and stored at MD Anderson and/or at a NIH designated facility such as the NGVB.

Exclusion Criteria:

• 1) Subject's gene transfer protocol is not approved at MD Anderson Cancer Center.